Double-Blind Comparison of Half-Dose and Standard-Dose Flupenthixol Decanoate in the Maintenance Treatment of Stabilised Out-Patients with Schizophrenia
The DOI matches its Crossref record.
Abstract
A double-blind controlled trial of 50% dose reduction in maintenance treatment in stable out-patients with low BPRS scores and good social function shows a significantly higher relapse rate in the low-dose group at 12 months (P < 0.05). After an interval of 24–36 months from dose reduction, 56–76% had experienced a relapse and 76–79% had resumed their former dosage. No clear advantage was shown for the lower dose in either a reduction of side-effects or improved social function, but a reduced prevalence or lower rate of symptom emergence for tardive dyskinesia was suggested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Guidelines for depot antipsychotic treatment in schizophrenia
Kane, J. M., Aguglia, E., Altamura, A. C., Gutierrez, J. L. A., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00045-x · Cited by 332
Schooler, N. R. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830170079011 · Cited by 298
Depot Antipsychotic Drugs: Place in Therapy
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295
Kane, J. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340109 · Cited by 272
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
“The results have been inconsistent, with some reporting positive outcomes (Hogarty et al., 1988; Inderbitzin et al., 1994; Schooler et al., 1997) and others negative ones (Kane et al., 1983; Cookson, 1987; Johnson et al., 1987; Kreisman et al., 1988; Faraone et al., 1989).”
BackgroundResultDetermining the optimal dose of haloperidol in first-episode psychosis
Oosthuizen, P., Emsley, R. A., Turner, J., & Keyter, N. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500403 · Cited by 48
“Not all of the evidence supports the use of low-dose conventional antipsychotics, however, with some suggesting poorer efficacy for low-dose oral (Zimbroff et al., 1997) or depot (Kane t al., 1983; Johnson et al., 1987; Marder et al., 1987) medication.”
Bogers, J. P. A. M., Hambarian, G., Michiels, M., Vermeulen, J., & de Haan, L. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa002 · Cited by 33
Wiedemann, G., Hahlweg, K., Müller, U., Feinstein, E., Hank, G., & Dose, M. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060170056 · Cited by 23
Bailey, L., & Taylor, D. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05311-2 · Cited by 21
Relapse Prevention: A Model for Psychosis?
Beck-Sander, A. (1999) · Behaviour Change · doi:10.1375/bech.16.3.191 · Cited by 4
Metadata
- Authors
- Johnson, D. A. W., Ludlow, J. M., Street, K., & Taylor, R. D. W.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1987-11
- Volume
- 151
- Issue
- 5
- Pages
- 634-638
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2027093916
- Cited by
- 110
- References
- 0
- FWCI
- 4.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.